Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.03 USD | -0.12% | -8.65% | +446.26% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+446.26% | 239M | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug